Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cervical Cancer: Page 2
Seegene develops '3 Ct' assay for HPV infection
By
LabPulse.com staff writers
The Allplex HPV HR assay detects 14 high-risk HPV types that cause cervical cancer. The assay provides the individual Ct value of each cancer type, allowing quantitative analysis to determine the infection level. The test is expected to be launched in the first half of 2022.
April 26, 2022
Dalrada Health completes cervical cancer screening kit trial
By
LabPulse.com staff writers
Results from the trial were published this month in the Indian Society of Perinatology and Reproductive Biology (IJOPARB) journal. Study participants were screened for cervical cancer with cerVIA, which showed an accuracy of 91%, according to the firm. The test is patent-pending, Dalrada said.
April 24, 2022
Dr. Elizabeth Stern: A pioneer in cytopathology screening
By
Louise Gagnon
Early years
March 28, 2022
Hologic receives CE Mark for Genius cervical cancer software
By
LabPulse.com staff writers
The new algorithm analyzes ThinPrep Pap images to narrow tens of thousands of cells down to an AI-generated gallery to find lesions and cancer cells. This arms healthcare providers with the critical information they need to guide earlier detection and better treatment decisions for the patients in their care, the company said.
November 3, 2021
How AI for cervical cancer can help achieve healthcare equity
By
Michael Quick
Thanks to screening programs and improvements in technology, mortality rates have been falling in high-income countries, yet rates within these regions still can affect populations drastically differently. For example, Black women in the U.S. are two times more likely to die from cervical cancer than white women.3
October 10, 2021
Mel-Mont validates self-sampling kit
By
LabPulse.com staff writers
Norwegian researchers tested the kit's performance in a group of 500 women at detecting rates of genital HPV infection compared to clinician-collected samples. The study found "fair agreement" of HPV positivity rates between the two methods, according to the authors. The study was published in BMC Infectious Diseases.
August 4, 2021
OptraScan launches cytology slide scanning device
By
LabPulse.com staff writers
CytoSiA consists of the company's digital pathology scanner, storage, and artificial intelligence (AI) algorithms for screening and detection of cervical cancer, precancerous lesions, and atypical cells. It can scan 15 x 15-mm cytology slides at 40x magnification in less than 60 sec, according to the firm.
May 24, 2021
Hologic wins CE Mark for cervical cancer screening system
By
LabPulse.com staff writers
After analyzing all cells on a ThinPrep Pap test slide, Genius Digital Diagnostics can provide a gallery view of the most diagnostically relevant images, Hologic said.
November 16, 2020
ACS cervical cancer guidelines disappoint some testing firms
By
LabPulse.com staff writers
The current standard of care is to use the Pap test for women ages 21 to 29 and a combination of both the Pap test and HPV test (cotesting) for women between the ages of 30 and 65. The ACS guidelines, which were published July 30, would shift to HPV testing only, and Hologic claims this would erode access to preventative healthcare and could sow confusion among women and their healthcare providers.
July 30, 2020
National cervical cancer screening guidelines shift to primary HPV testing
By
Emily Hayes
The ACS published a 2020 update to guidelines for cervical cancer screening for individuals at average risk in its publication CA: A Cancer Journal for Clinicians online July 30. Guidelines were last updated in 2012.
July 30, 2020
HPV, Pap cotesting best for cervical cancer detection in Quest study
By
Melissa Busch, LabPulse.com assistant editor; Emily Hayes, editor in chief
Cotesting involves Pap and HPV screening using the same specimen. A new study of women 30 years or older by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center found that cotesting outperformed HPV or Pap testing alone for detecting precancer or cancer. In the retrospective study, the researchers evaluated deidentified results for tests conducted between 2010 and 2018 by Quest in 13.6Â million women; 8,059 had precancers and 1,259 were subsequently diagnosed with cervical cancer.
July 8, 2020
Machine learning could 'transform' cervical cancer screening, NCI researchers report
By
Emily Hayes
The NCI researchers described positive experiences with Cytoreader, an automated system for evaluating digital dual-stained whole-slide images for the protein biomarkers p16 and Ki-67, using data from three epidemiology studies of patients with cervical and anal cancers who were positive for human papillomavirus (HPV). The automated system assesses the number of dual-stained positive cells and flags the ones that exceed predefined cutoff points.
June 25, 2020
Previous Page
Page 2 of 3
Next Page